CH637297A5
(fr)
*
|
1978-12-05 |
1983-07-29 |
Nestle Sa |
Microbille comprenant un microorganisme et son procede de fabrication.
|
US4421736A
(en)
*
|
1982-05-20 |
1983-12-20 |
Merrel Dow Pharmaceuticals Inc. |
Sustained release diethylpropion compositions
|
US4507276A
(en)
*
|
1982-08-20 |
1985-03-26 |
Bristol-Myers Company |
Analgesic capsule
|
FR2548021B1
(fr)
*
|
1983-06-29 |
1986-02-28 |
Dick P R |
Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
|
NL8500724A
(nl)
*
|
1985-03-13 |
1986-10-01 |
Univ Groningen |
Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
|
US4755387A
(en)
*
|
1985-03-21 |
1988-07-05 |
The Procter & Gamble Company |
Therapeutic particles
|
US4863741A
(en)
*
|
1985-03-25 |
1989-09-05 |
Abbott Laboratories |
Tablet composition for drug combinations
|
US4874614A
(en)
*
|
1985-03-25 |
1989-10-17 |
Abbott Laboratories |
Pharmaceutical tableting method
|
CA1279574C
(en)
*
|
1985-04-17 |
1991-01-29 |
Jeffrey L. Finnan |
Process for lubricating water-soluble vitamin powders
|
US4728512A
(en)
*
|
1985-05-06 |
1988-03-01 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US4904476A
(en)
*
|
1986-03-04 |
1990-02-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US4794001A
(en)
*
|
1986-03-04 |
1988-12-27 |
American Home Products Corporation |
Formulations providing three distinct releases
|
US5019302A
(en)
*
|
1986-03-12 |
1991-05-28 |
Washington University Technology Associates, Inc. |
Method for granulation
|
FI77573C
(fi)
*
|
1987-05-08 |
1989-04-10 |
Orion Yhtymae Oy |
Ny konsistens.
|
JP2668880B2
(ja)
*
|
1987-06-23 |
1997-10-27 |
日本油脂株式会社 |
被覆アミノ酸類の製造方法
|
DE3721721C1
(de)
*
|
1987-07-01 |
1988-06-09 |
Hoechst Ag |
Verfahren zur Umhuellung von Granulaten
|
US5133974A
(en)
*
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
US5328697A
(en)
*
|
1992-02-10 |
1994-07-12 |
Mallinckrodt Veterinary, Inc. |
Compositions and processes for the sustained release of drugs
|
AP1905A
(en)
|
1999-12-10 |
2008-10-20 |
Pfizer Prod Inc |
Pyrrolo[2,3-d] Pyrimidine Compounds.
|
US6544555B2
(en)
*
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
CA2404626A1
(en)
*
|
2000-03-31 |
2001-10-04 |
Pfizer Products Inc. |
Novel piperazine derivatives
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
YU30603A
(sh)
*
|
2000-10-19 |
2006-05-25 |
Pfizer Products Inc. |
Derivati premošćenog piperazina
|
BR0210531A
(pt)
*
|
2001-06-20 |
2004-06-22 |
Pfizer Prod Inc |
Derivados de ácido sulfÈnico
|
CA2463272C
(en)
*
|
2001-10-22 |
2009-11-17 |
Laura Cook Blumberg |
Piperazine derivatives with ccr1 receptor antagonist activity
|
WO2003095439A1
(en)
*
|
2002-05-14 |
2003-11-20 |
Pfizer Products Inc. |
Methods for manufacture of dihydro-furan-2-one derivatives
|
RU2004133530A
(ru)
*
|
2002-05-14 |
2005-06-10 |
Пфайзер Продактс Инк. (Us) |
Производные дигидроксигексановой кислоты, их промежуточные соединения и способы получения
|
PA8575901A1
(es)
*
|
2002-07-18 |
2004-07-20 |
Pfizer Prod Inc |
Derivados de piperidina novedosos
|
OA12894A
(en)
*
|
2002-08-12 |
2006-10-13 |
Pfizer Prod Inc |
Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoy 1-1-(3-fluorobenzyl)-2,7-dihydroxy-7-met hyl-octyl]-amide.
|
DE60330362D1
(de)
|
2002-09-18 |
2010-01-14 |
Pfizer Prod Inc |
Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
|
US20040097554A1
(en)
*
|
2002-10-30 |
2004-05-20 |
Pfizer Inc |
Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
|
US20040087571A1
(en)
*
|
2002-10-30 |
2004-05-06 |
Pfizer Inc |
Methods of using CCR1 antagonists as immunomodulatory agents
|
US20040116441A1
(en)
*
|
2002-10-30 |
2004-06-17 |
Pfizer Inc |
Methods of using sulfonic acid derivatives
|
KR100742012B1
(ko)
*
|
2002-11-21 |
2007-07-23 |
화이자 프로덕츠 인코포레이티드 |
3-아미노-피페리딘 유도체 및 그의 제조 방법
|
BR0316487A
(pt)
*
|
2002-11-26 |
2005-10-11 |
Pfizer Prod Inc |
Método todo de tratamento da rejeição de transplantes
|
BR0317244A
(pt)
*
|
2002-12-13 |
2005-11-01 |
Pfizer Prod Inc |
Derivados de piperazina contendo fósforo como antagonistas ccr1
|
PA8591801A1
(es)
|
2002-12-31 |
2004-07-26 |
Pfizer Prod Inc |
Inhibidores benzamidicos del receptor p2x7.
|
BRPI0407384A
(pt)
*
|
2003-02-14 |
2006-02-21 |
Pfizer Prod Inc |
piridinas-triazóis como compostos antiinflamatórios
|
PA8595001A1
(es)
*
|
2003-03-04 |
2004-09-28 |
Pfizer Prod Inc |
Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
|
JP2006519833A
(ja)
|
2003-03-11 |
2006-08-31 |
ファイザー・プロダクツ・インク |
トランスフォーミング成長因子(tgf)阻害剤としてのピラジン化合物
|
US20050119275A1
(en)
*
|
2003-06-24 |
2005-06-02 |
Pfizer Inc. |
Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
|
EP1689407A1
(en)
*
|
2003-11-25 |
2006-08-16 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
TW201038578A
(en)
|
2009-01-30 |
2010-11-01 |
Univ Rutgers |
Methods to treat cancer
|
US8461102B2
(en)
*
|
2010-03-02 |
2013-06-11 |
George E. Royster, JR. |
Methods and compositions for treating and preventing symptoms of hormonal variations
|
TWI546301B
(zh)
|
2011-03-18 |
2016-08-21 |
健臻公司 |
葡萄糖神經醯胺合成酶抑制劑
|
BR112013029482A2
(pt)
|
2011-05-16 |
2016-08-09 |
Genzyme Corp |
utilização de antagonistas cxr4
|
CA2844577A1
(en)
|
2011-09-13 |
2013-03-21 |
Ottawa Hospital Research Institute |
Microrna inhibitors
|
JOP20130273B1
(ar)
|
2012-09-11 |
2021-08-17 |
Genzyme Corp |
مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
|
RU2015143526A
(ru)
|
2013-03-13 |
2017-04-19 |
Бостон Байомедикал, Инк. |
Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
|
JP2016539927A
(ja)
|
2013-10-24 |
2016-12-22 |
アッヴィ・インコーポレイテッド |
Jak1選択的阻害剤とその使用
|
WO2016016370A1
(en)
|
2014-07-31 |
2016-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 receptor antagonists
|
MA41202A
(fr)
|
2014-12-18 |
2017-10-24 |
Genzyme Corp |
Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
|
EP3265462A1
(en)
|
2015-03-03 |
2018-01-10 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Fgfr3 antagonists
|
TW201642855A
(zh)
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
US20200181089A1
(en)
|
2016-07-08 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
4-anilino-quinoline compounds as anti-cancer agents
|
CN112055706B
(zh)
|
2018-01-05 |
2023-11-10 |
健康和医学国家研究院 |
取代的卤代-喹啉衍生物、其制备方法和应用
|
ES2967517T3
(es)
|
2018-10-03 |
2024-04-30 |
Tesaro Inc |
Sales de niraparib
|
US20210347758A1
(en)
|
2018-10-03 |
2021-11-11 |
Tesaro, Inc. |
Crystalline Forms of Niraparib Freebase
|
JP2022519131A
(ja)
|
2019-02-04 |
2022-03-18 |
ジェンザイム・コーポレーション |
グルコシルセラミドシンターゼ(gcs)阻害剤を使用した繊毛病の処置
|
BR112021015099A2
(pt)
|
2019-02-04 |
2021-10-05 |
Genzyme Corporation |
Métodos para tratar sintomas e distúrbios associados a doenças de armazenamento lisossômico
|
TW202142236A
(zh)
|
2020-02-03 |
2021-11-16 |
美商健臻公司 |
用於治療與溶體儲積症相關的神經症狀之方法
|
EP4185267A1
(en)
|
2020-07-24 |
2023-05-31 |
Genzyme Corporation |
Pharmaceutical compositions comprising venglustat
|
EP4221700A1
(en)
|
2020-09-30 |
2023-08-09 |
Bioverativ Therapeutics Inc. |
Ampk activators and methods of use thereof
|
TW202241888A
(zh)
|
2020-12-23 |
2022-11-01 |
美商健臻公司 |
氘化群落刺激因子-1受體(csf-1r)抑制劑
|
WO2023196640A1
(en)
|
2022-04-08 |
2023-10-12 |
Bioverativ Therapeutics Inc. |
Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
|
WO2024116127A1
(en)
|
2022-12-01 |
2024-06-06 |
Genzyme Corporation |
Venglustat in combination with a strong or moderate inhibitor of cyp3a4
|